A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy

Table 1 Clinicopathologic variables of 325 T2N0M0 gastric cancer patients

Variable	Overall	Adjuvant chemotherapy group	Postoperative observation group	P value
	325	63	262
Age (yr) n (%)				0.609
< 40	20 (6.2)	3 (4.8)	17 (6.5)
≥ 40	305 (93.8)	60 (95.2)	245 (93.5)
Sex, n (%)				0.878
Male	250 (76.9)	48 (76.2)	202 (77.1)
Female	75 (23.1)	15 (23.8)	60 (22.9)
Smoking history, n (%)				0.363
Yes	169 (52.0)	36 (57.1)	133 (50.8)
No	156 (48.0)	27 (42.9)	129 (49.2)
Family history of gastric cancer, n (%)				0.852
Yes	24 (7.4)	5 (7.9)	19 (7.3)
No	301 (92.6)	58 (92.1)	243 (92.7)
BMI, n (%)				0.150
< 18.5 or > 23.9	176 (54.2)	29 (46.0)	147 (56.1)
18.5-23.9	149 (45.8)	34 (54.0)	115 (43.9)
Postoperative hospital stay, n (%)				0.747
≤ 14 d	285 (87.7)	56 (88.9)	229 (87.4)
> 14 d	40 (12.3)	7 (11.1)	33 (12.6)
Tumor site, n (%)				0.004
Cardia cancer	105 (32.3)	30 (47.6)	75 (28.6)
Non-cardia gastric cancer	220 (67.7)	33 (52.4)	187 (71.4)
The degree of differentiation, n (%)				0.571
Poorly differentiated	121 (37.2)	24 (38.1)	97 (37.0)
Moderately differentiated	178 (54.8)	36 (57.1)	142 (54.2)
Highly differentiated	26 (8.0)	3 (4.8)	23 (8.8)
Vascular invasion, n (%)				0.014
Yes	54 (16.6)	17 (27.0)	37 (14.1)
No	271 (83.4)	46 (73.0)	225 (85.9)

BMI: Body mass index.